Immunovant, Inc. Reports 2026 Annual Meeting Vote Results

What Happened
Immunovant, Inc. (IMVT) filed an 8-K on Sept. 3, 2026 reporting the results of its Sept. 2, 2026 Annual Meeting of Stockholders. Approximately 198,373,370 shares were represented (about 96% of shares entitled to vote). Stockholders elected three directors, ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2027, and approved, on a non‑binding advisory basis, the compensation of the company’s named executive officers.

Key Details

• Vote turnout: 198,373,370 shares represented (~96% of voting shares).
• Directors elected (terms until the 2027 Annual Meeting):
  • Jacob Bauer — For: 162,872,114; Withheld: 26,430,450; Broker non‑votes: 9,070,806
  • Douglas Hughes — For: 174,053,304; Withheld: 15,249,260; Broker non‑votes: 9,070,806
  • Robert Susman — For: 181,604,476; Withheld: 7,698,088; Broker non‑votes: 9,070,806
• Auditor ratification: Ernst & Young LLP ratified — For: 198,148,265; Against: 187,390; Abstain: 37,715.
• Say‑on‑pay (advisory): Approved — For: 180,772,822; Against: 8,437,839; Abstain: 91,903; Broker non‑votes: 9,070,806.
• 8‑K signed by CFO Tiago Girao on Sept. 3, 2026; full proxy statement filed July 22, 2026.

Why It Matters
These results confirm the company’s board composition and auditor for the coming fiscal year and show strong shareholder participation and support for management’s compensation program (though the pay vote is non‑binding). For investors, the outcomes affect governance oversight, auditor continuity, and provide a gauge of shareholder sentiment toward executive pay and board stewardship.